论文部分内容阅读
目的探究胃泌素释放肽前体(Pro-GRP)在小细胞肺癌(SCLC)诊断中的应用价值。方法将38例SCLC患者作为A组,50例非小细胞肺癌(NSCLC)患者为B组,分别检测两组血清患者Pro-GRP、神经特异性烯醇化酶(NSE)水平及其阳性率,并进行比较。结果 A组中血清Pro-GRP水平及NSE水平均明显高于B组(P<0.05)。A组血清Pro-GRP及NSE的阳性率分别为71.05%、47.37%,B组分别6.00%、38.00%,A组Pro-GRP阳性率高于B组(P<0.05),两组NSE阳性率比较差异无统计学意义(P>0.05)。结论血清Pro-GRP用于诊断小细胞肺癌效果优于NSE,具有较高诊断价值,值得临床推广。
Objective To investigate the value of gastrin-releasing peptide (Pro-GRP) in the diagnosis of small cell lung cancer (SCLC). Methods 38 patients with SCLC were selected as group A and 50 patients with non-small cell lung cancer (NSCLC) as group B. Serum levels of Pro-GRP, NSE and their positive rates Compare. Results Serum levels of Pro-GRP and NSE in group A were significantly higher than those in group B (P <0.05). The positive rates of Pro-GRP and NSE in group A were 71.05% and 47.37% respectively, while those in group B were 6.00% and 38.00% respectively. The positive rate of Pro-GRP in group A was higher than that in group B (P <0.05) The difference was not statistically significant (P> 0.05). Conclusion The serum Pro-GRP is superior to NSE in the diagnosis of small cell lung cancer, which is of high diagnostic value and worthy of clinical promotion.